---
title: "$0.13-$0.15 price target for OP by March-end, indicating possible 8-25% gains amidst technical recovery."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278733130.md"
description: "An analysis of OP price predicts a possible increase of 8-25% to a range of $0.13 to $0.15 by the end of the month. Optimism is challenging crucial resistance levels despite ongoing bearish momentum indicators."
datetime: "2026-03-11T13:16:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278733130.md)
  - [en](https://longbridge.com/en/news/278733130.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278733130.md)
---

# $0.13-$0.15 price target for OP by March-end, indicating possible 8-25% gains amidst technical recovery.

An analysis of OP price predicts a possible increase of 8-25% to a range of $0.13 to $0.15 by the end of the month. Optimism is challenging crucial resistance levels despite ongoing bearish momentum indicators.

### Related Stocks

- [OHCS.US](https://longbridge.com/en/quote/OHCS.US.md)
- [OPUSD.VAHK](https://longbridge.com/en/quote/OPUSD.VAHK.md)

## Related News & Research

- [Optimism price prediction 2026–2032: Will OP token gain momentum?](https://longbridge.com/en/news/294919684.md)
- [Can Caterpillar (CAT) Justify Its Valuation As AI Data Center Optimism Meets Earnings?](https://longbridge.com/en/news/294635551.md)
- [Cocoa Prices Slip as Overbought Conditions Spur Technical Selling](https://longbridge.com/en/news/294849133.md)
- [Leopold Aschenbrenner's hedge-fund implosion offers 3 investing lessons for everyone](https://longbridge.com/en/news/294673772.md)
- [Opus Genetics completes enrollment in Phase 3 trial of OPGx-LCA5 gene therapy for LCA5 retinal disease](https://longbridge.com/en/news/294682847.md)